Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Inclusion Criteria:

• Patients with symptomatic active multiple myeloma who have completed autotransplantare eligible for the study; patients should be assessed for eligibility within 35 daysof the transplant and treatment should commence within 10 weeks of the transplant

• Performance status of 0-2 based on Southwest Oncology Group (SWOG) criteria; patientswith a poor performance status (3-4) are also eligible, if complications of the bonesuch as compression fracture, hyperviscosity or infection such as pneumonia have beenadequately treated

• No significant co-morbid medical conditions; no uncontrolled life threateninginfection

• Unsupported platelet count > 80,000/uL

• Absolute neutrophil count (ANC) > 1000/uL

• Signed informed consent should be obtained from all patients in accordance withinstitutional and federal guidelines

Exclusion Criteria:

• Patients with a history of recent (< 6 months) myocardial infarction, unstable angina,difficult to control congestive heart failure, uncontrolled hypertension, difficult tocontrol significant cardiac arrhythmias, or arrhythmia associated with prolonged QTinterval

• Pregnant or nursing women; women of child-bearing potential must have a negativepregnancy documented within one week of registration; women/men of reproductivepotential may not participate unless they have agreed to use two forms of effectivecontraceptive method

• Patients with a grade 3-4 neuropathy related to prior exposure to bortezomib,thalidomide, or other agents

• Human immunodeficiency virus (HIV) positive patients

• Transaminases > 2 x normal values

• Bilirubin > 2 x normal values

• Active uncontrolled infection

• History of significant psychiatric illness; steroid induced psychosis